Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Illumina stock

ILMN
US4523271090
927079

Price

0
Today +/-
-0
Today %
-0 %

Illumina stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Illumina stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Illumina stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Illumina stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Illumina's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Illumina Stock Price History

DateIllumina Price
2/19/20250 undefined
2/17/2025101.09 undefined
2/13/2025100.24 undefined
2/12/2025101.78 undefined
2/11/2025103.57 undefined
2/10/2025100.68 undefined
2/9/2025104.99 undefined
2/6/2025111.06 undefined
2/5/2025122.80 undefined
2/4/2025124.68 undefined
2/3/2025124.20 undefined
2/2/2025131.10 undefined
1/30/2025132.74 undefined
1/29/2025133.01 undefined
1/28/2025131.72 undefined
1/27/2025133.61 undefined
1/26/2025138.05 undefined
1/23/2025136.22 undefined
1/22/2025134.76 undefined
1/21/2025140.36 undefined
1/20/2025141.31 undefined

Illumina Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Illumina, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Illumina from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Illumina’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Illumina. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Illumina’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Illumina’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Illumina’s growth potential.

Illumina Revenue, EBIT and net profit per share

DateIllumina RevenueIllumina EBITIllumina Net Income
2030e6.77 B undefined0 undefined1.64 B undefined
2029e5.91 B undefined1.63 B undefined1.26 B undefined
2028e5.45 B undefined1.46 B undefined1.11 B undefined
2027e4.98 B undefined1.26 B undefined938.97 M undefined
2026e4.66 B undefined1.11 B undefined832.99 M undefined
2025e4.43 B undefined987.86 M undefined731.68 M undefined
20244.37 B undefined661 M undefined-1.22 B undefined
20234.5 B undefined-76 M undefined-1.16 B undefined
20224.58 B undefined354 M undefined-4.4 B undefined
20214.53 B undefined-123 M undefined762 M undefined
20203.24 B undefined580 M undefined656 M undefined
20193.54 B undefined985 M undefined1 B undefined
20183.33 B undefined883 M undefined826 M undefined
20172.75 B undefined629 M undefined726 M undefined
20162.4 B undefined579 M undefined462.6 M undefined
20152.22 B undefined623.1 M undefined461.6 M undefined
20141.86 B undefined447.6 M undefined353.4 M undefined
20131.42 B undefined254.1 M undefined125.3 M undefined
20121.15 B undefined233.4 M undefined151.3 M undefined
20111.06 B undefined250.4 M undefined86.6 M undefined
2010902.7 M undefined203.2 M undefined124.9 M undefined
2009666.3 M undefined136.9 M undefined72.3 M undefined
2008573.2 M undefined109.2 M undefined39.4 M undefined
2007366.8 M undefined56.7 M undefined-287.3 M undefined
2006184.6 M undefined37.8 M undefined40 M undefined
200573.5 M undefined-5.6 M undefined-20.9 M undefined

Illumina Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
00000.010.030.050.070.180.370.570.670.91.061.151.421.862.222.42.753.333.543.244.534.584.54.374.434.664.985.455.916.77
---100.00400.00180.0078.5746.00152.0598.9156.5616.2335.4416.968.8223.7830.9619.248.0714.7621.116.30-8.5839.731.28-1.75-2.931.405.176.899.278.5814.58
--286,100.0050.0060.0064.2974.0068.4967.9363.1162.3068.0266.6367.2067.3364.1169.6969.8169.4767.0169.0169.6368.0169.6964.8360.9265.4464.5461.3757.4252.5448.3942.24
00000.010.020.040.050.130.230.360.450.60.710.770.911.31.551.671.842.32.472.23.152.972.742.86000000
-0-0.01-0.02-0.02-0.04-0.03-0.01-0.020.04-0.290.040.070.120.090.150.130.350.460.460.730.8310.660.76-4.4-1.16-1.220.730.830.941.111.261.64
-400.00260.0033.3366.67-32.50-77.78233.33-300.00-817.50-113.5984.6272.22-30.6575.58-17.22182.4030.590.2257.1413.7721.31-34.5316.16-677.95-73.645.34-159.7713.8212.7418.5513.2230.02
1.32.827.159.561.863.971.780.397.5108.3133.6137.1143.4138.9133.7139.9149149.1148148149149148151157158159000000
---------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Illumina Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Illumina is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                     
0.010.030.120.090.050.030.060.050.130.390.640.690.891.191.351.171.341.391.562.153.513.413.471.342.041.051.22
00113512184082131156163171213238287385381411514573487648688752751
006010000122332121000000000
00012241020547393142129159154191271300333386359372431568587547
00531311313402338565263597154789178105152295268216228
0.010.030.130.10.070.040.080.080.190.560.870.981.261.551.791.621.892.12.322.984.494.454.482.713.562.612.75
0000.030.050.050.010.020.030.050.090.120.130.140.170.20.270.340.710.931.081.441.451.71.741.551.23
000001200680560000000000000211196227
000000000000000000000000000
0000000000.060.050.040.090.110.130.330.320.270.240.180.190.150.143.253.292.990.3
0000000000.230.210.210.280.320.370.720.730.750.780.770.830.820.97.113.242.551.11
00000000119251748179113145145222231400378452609445212217688
0000.030.050.060.010.020.110.430.460.450.580.650.781.41.451.591.962.282.472.873.112.58.697.53.56
0.010.030.130.120.120.10.10.10.30.991.331.431.842.22.573.023.343.694.285.266.967.327.5915.2212.2510.116.3
                                                     
9370000000111222222222222222
00.010.160.160.160.170.20.220.341.041.471.641.892.252.422.562.172.52.732.833.293.563.828.949.219.567.53
-0-0.01-0.03-0.05-0.09-0.12-0.12-0.15-0.11-0.38-0.35-0.28-0.16-0.070.080.210.561.021.492.263.084.074.725.491.14-0.02-1.24
0-4-14-7-3-1001111111111111111173-122
0000000000110110-2-1-2-2-2410000
0.010.030.120.110.070.050.070.070.250.661.121.361.742.192.512.772.743.524.225.096.377.638.5414.4410.359.546.31
00122237102429536750667483139138160184149192332293245221
00231261611173048538287109124201235392376256263287429890994466
000000037112324674909395135162173200257253254332342331361
000000000000000000000000000
00000000000.280.290.3100.040.030.30.0800.011.1100.5101.2500.5
0000.010.020.010.020.020.030.170.390.440.540.230.310.320.720.610.70.751.80.671.241.092.771.571.55
00000.030.030000.40000.810.810.970.991.021.051.180.891.140.671.71.491.491.49
000000007000000000000000000
000.010.010.010.0200.010.010.010.140.120.110.090.140.190.170.180.210.360.360.90.971.691.391.310.89
000.010.010.040.0400.010.020.410.140.120.110.890.941.161.161.21.261.541.252.041.653.382.882.82.38
000.010.020.050.050.020.030.050.580.530.570.641.121.251.491.881.811.972.293.052.72.894.485.654.373.93
0.010.030.130.120.120.10.10.10.31.241.651.932.383.313.764.264.615.336.197.389.4310.3411.4318.9216.0113.910.24
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Illumina provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Illumina's financial health and stability.

Assets

Illumina's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Illumina must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Illumina after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Illumina's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005nullnull20062007200820092010null2011nullnull20122013201420152016nullnull2017201820192020202120222023
-1-5-18-24-40-27-6-20-6-2040-2873972124728612486151125353458428458428678782990656762-4,404-1,161
0001444343613273142316842686397112127141127141156179188187251394432
00000000000-1731-2048-20194819-21-36998194819481-1811117-76-23-33
01-4651-18-7-18-7-1913-8834-23435-235-1820-56-40-45-40-45195-18-19473-152204-90
000.010.010.01000.0200.020.010.330.130.120.130.050.240.060.150.210.290.140.290.290.160.16-0.070.410.250.240.514.591.71
0000221010012202202200000000000073
000000000012-110010909745017176017601499916411923312265
-0-0-0.01-0.01-0.03-0.02-0.02-0.01-0.02-0.010.040.060.090.170.270.170.360.270.360.290.390.50.790.780.790.780.881.141.051.080.550.390.48
00-3-15-27-2-3-11-3-11-15-24-95-56-56-56-79-56-79-81-90-142-143-271-143-271-312-296-209-189-208-466-196
0-126-101-22857-157-1-160-67-277-256-285-256-401-285-401-150-69-406-107-515-107-515-214-1,813745-554-1,069-591-231
0-129-862530609609-145-43-181-200-228-200-321-228-321-6920-26436-24436-24498-1,517954-365-861-125-35
000000000000000000000000000000000
00000.030-0.030-0.03000.250-0.010-0.010.5500.550-0.011.1-0.25-0.06-0.25-0.06-00.73-0.5500.470.99-1.24
928102000306306108-122319-12874-128-50374-503-28-80-140-202-202-202-202-180-155-265-675606367
92810302604646109148337-98116-989711697-10-38-166-545-296-545-296-176594-897-766-511,000-1,210
0000000000120183942394642461752-1,128-98-33-98-33818-82-91-582-54-42
000000000000000000000000000000000
81295-111-21042-342-4-12136152-182104-1825410454131277-75133-34133-34490-81898-232-578779-963
-1.1-3.2-17.7-25.9-53.2-20.3-23-20.40023.831.9-7.8116.1216.10278.500210.9295.8359.164350800563846842891337-74282
000000000000000000000000000000000

Illumina stock margins

The Illumina margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Illumina. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Illumina.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Illumina's sales revenue. A higher gross margin percentage indicates that the Illumina retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Illumina's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Illumina's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Illumina's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Illumina. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Illumina's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Illumina Margin History

Illumina Gross marginIllumina Profit marginIllumina EBIT marginIllumina Profit margin
2030e65.44 %0 %24.17 %
2029e65.44 %27.52 %21.3 %
2028e65.44 %26.83 %20.44 %
2027e65.44 %25.33 %18.84 %
2026e65.44 %23.83 %17.87 %
2025e65.44 %22.28 %16.51 %
202465.44 %15.12 %-27.97 %
202360.92 %-1.69 %-25.78 %
202264.83 %7.72 %-96.07 %
202169.69 %-2.72 %16.84 %
202068.01 %17.91 %20.25 %
201969.63 %27.8 %28.28 %
201869.01 %26.49 %24.78 %
201767.01 %22.86 %26.38 %
201669.48 %24.14 %19.29 %
201569.79 %28.07 %20.79 %
201469.72 %24.05 %18.99 %
201364.16 %17.88 %8.82 %
201267.35 %20.32 %13.17 %
201167.18 %23.72 %8.2 %
201066.63 %22.51 %13.84 %
200968.12 %20.55 %10.85 %
200862.32 %19.05 %6.87 %
200763.22 %15.46 %-78.33 %
200667.82 %20.48 %21.67 %
200568.44 %-7.62 %-28.44 %

Illumina Stock Sales Revenue, EBIT, Earnings per Share

The Illumina earnings per share therefore indicates how much revenue Illumina has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Illumina earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Illumina's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Illumina’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Illumina's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Illumina Revenue, EBIT and net profit per share

DateIllumina Sales per ShareIllumina EBIT per shareIllumina Earnings per Share
2030e42.71 undefined0 undefined10.32 undefined
2029e37.28 undefined0 undefined7.94 undefined
2028e34.33 undefined0 undefined7.02 undefined
2027e31.42 undefined0 undefined5.92 undefined
2026e29.39 undefined0 undefined5.25 undefined
2025e27.95 undefined0 undefined4.61 undefined
202427.5 undefined4.16 undefined-7.69 undefined
202328.51 undefined-0.48 undefined-7.35 undefined
202229.2 undefined2.25 undefined-28.05 undefined
202129.97 undefined-0.81 undefined5.05 undefined
202021.89 undefined3.92 undefined4.43 undefined
201923.78 undefined6.61 undefined6.72 undefined
201822.37 undefined5.93 undefined5.54 undefined
201718.59 undefined4.25 undefined4.91 undefined
201616.21 undefined3.91 undefined3.13 undefined
201514.89 undefined4.18 undefined3.1 undefined
201412.49 undefined3 undefined2.37 undefined
201310.16 undefined1.82 undefined0.9 undefined
20128.59 undefined1.75 undefined1.13 undefined
20117.6 undefined1.8 undefined0.62 undefined
20106.29 undefined1.42 undefined0.87 undefined
20094.86 undefined1 undefined0.53 undefined
20084.29 undefined0.82 undefined0.29 undefined
20073.39 undefined0.52 undefined-2.65 undefined
20061.89 undefined0.39 undefined0.41 undefined
20050.92 undefined-0.07 undefined-0.26 undefined

Illumina business model

Illumina Inc. is an American company founded in 1998 and based in San Diego. The company is a leading provider of technology tools for DNA and RNA analysis. Illumina has revolutionized genome research and the development of personalized medicine. Illumina is one of the most popular companies on Eulerpool.com.

Illumina SWOT Analysis

Strengths

Illumina Inc. is a leading provider of sequencing and array-based technologies for genetic analysis. The company's strengths include:

  • Strong market position: Illumina holds a significant market share in the genetic sequencing and analysis industry, making it a leader in the field.
  • Robust product portfolio: The company offers a wide range of innovative products and solutions, catering to diverse research and clinical applications.
  • Advanced technology: Illumina's cutting-edge sequencing platforms and bioinformatics tools are known for their accuracy, speed, and scalability.
  • Strong research and development capabilities: Illumina invests heavily in R&D, allowing it to continuously develop and launch new products to stay ahead of the competition.

Weaknesses

Despite its strengths, Illumina Inc. also faces certain weaknesses that could impede its growth and competitiveness:

  • High product and service costs: Illumina's technologies and services can be expensive, limiting accessibility for some customers and hindering adoption in certain markets.
  • Dependence on key customers: The company's revenues are heavily reliant on a few major customers, leaving it vulnerable to client-specific risks.
  • Regulatory challenges: Illumina operates in a highly regulated industry, requiring compliance with various local and international regulations, which can limit its flexibility and increase operational costs.
  • Limited geographic presence: Although Illumina has a global reach, its market penetration is not evenly distributed worldwide, leaving certain regions underrepresented.

Opportunities

To sustain its growth and expand its business, Illumina Inc. can capitalize on several opportunities:

  • Increasing demand for genomic medicine: The growing understanding of genetics and personalized medicine presents a significant opportunity for Illumina to provide genetic testing and analysis services for healthcare purposes.
  • Emerging markets: Illumina can focus on expanding its presence in developing countries where there is a rising demand for genetic analysis technologies, such as China and India.
  • Partnerships and collaborations: Collaborating with research institutions, pharmaceutical companies, and other industry players can lead to new product development and mutual benefits.
  • Technological advancements: Continuously improving its existing technologies, developing new sequencing methods, and exploring other genetic analysis techniques can open up new avenues for Illumina's growth.

Threats

Illumina Inc. faces certain threats that could impact its market position and profitability:

  • Competition: The genetic sequencing and analysis market is highly competitive, with several established players as well as new entrants offering alternative technologies and solutions.
  • Intellectual property disputes: Legal battles related to patents and intellectual property rights can divert resources, damage reputation, and hinder product development.
  • Data privacy concerns: As genetic sequencing generates a vast amount of personal data, any data breaches or misuse can harm Illumina's reputation and lead to regulatory scrutiny.
  • Technology obsolescence: Rapid advancements in the field of genetic analysis can render existing technologies obsolete, requiring continuous innovation and adaptation.

Illumina Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Illumina Revenue by Segment

Segmente202320232022
Product revenue3.95 B USD3.79 B USD3.97 B USD
Service and other revenue631 M USD717 M USD558 M USD
Total product revenue---

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Illumina Revenue by Segment

Segmente202320232022
Consumables3.23 B USD3.08 B USD3.22 B USD
Instruments728 M USD704 M USD751 M USD
Other product---
Service and other revenue---

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Illumina Revenue by Segment

Segmente202320232022
Consumables---
Instruments---

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Illumina Revenue by Segment

Segmente202320232022
Sequencing4.17 B USD4.11 B USD4.11 B USD
Microarray413 M USD392 M USD417 M USD

Illumina Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Illumina Revenue by Segment

DateAmericasAsia-PacificAsia-Pacific, Middle East and AfricaEuropeEurope, Middle East, and AfricaGreater ChinaUnited States
20232.52 B USD-459 M USD1.14 B USD-384 M USD2.36 B USD
20232.48 B USD418 M USD--1.22 B USD472 M USD2.29 B USD
20222.36 B USD377 M USD--1.29 B USD502 M USD2.2 B USD
20211.74 B USD267 M USD--886 M USD342 M USD1.66 B USD
20191.97 B USD268 M USD--933 M USD372 M USD1.86 B USD
20181.86 B USD253 M USD--851 M USD365 M USD1.78 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Illumina Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Illumina historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Illumina shares outstanding

The number of shares was Illumina in 2024 — This indicates how many shares 159 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Illumina earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Illumina's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Illumina’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Illumina's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Illumina stock splits

In Illumina's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Illumina.

Illumina latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20240.93 0.86  (-7.76 %)2024 Q4
9/30/20240.9 1.14  (26.88 %)2024 Q3
6/30/20240.92 0.36  (-60.92 %)2024 Q2
3/31/20240.04 0.09  (118.98 %)2024 Q1
12/31/20230.02 0.14  (669.23 %)2023 Q4
9/30/20230.13 0.33  (162.32 %)2023 Q3
6/30/20230.02 0.32  (1,602.13 %)2023 Q2
3/31/20230.03 0.08  (210.08 %)2023 Q1
12/31/20220.11 0.14  (32.08 %)2022 Q4
9/30/20220.3 0.34  (11.88 %)2022 Q3
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Illumina stock

Eulerpool World ESG Rating (EESG©)

67/ 100

🌱 Environment

75

👫 Social

85

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
17,993
Scope 2 - Indirect emissions from purchased energy
21,137
Scope 3 - Indirect emissions within the value chain
299,025
Total CO₂ emissions
39,130
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees45
Percentage of women in management
Percentage of Asian employees34
Share of Asian management27
Percentage of Hispanic/Latino employees10
Hispano/Latino Management share9
Percentage of Black employees2
Black Management Share2
Percentage of white employees48
White Management Share58
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Illumina shareholders

%
Name
Stocks
Change
Date
11.36526 % Capital World Investors18,025,3011,214,44112/31/2024
9.92723 % The Vanguard Group, Inc.15,744,588-197,95812/31/2024
8.84449 % BlackRock Institutional Trust Company, N.A.14,027,367262,46612/31/2024
5.45631 % Capital Research Global Investors8,653,7127,576,87612/31/2024
3.65294 % State Street Global Advisors (US)5,793,557185,73312/31/2024
2.65458 % Loomis, Sayles & Company, L.P.4,210,160-132,58012/31/2024
2.60394 % WCM Investment Management4,129,855867,67312/31/2024
1.90302 % Baillie Gifford & Co.3,018,193-604,62012/31/2024
1.72362 % Geode Capital Management, L.L.C.2,733,6605,83312/31/2024
1.54844 % PRIMECAP Management Company2,455,819-60,54012/31/2024
1
2
3
4
5
...
10

Illumina Executives and Management Board

Ms. Susan Tousi

(55)
Illumina Chief Commercial Officer
Compensation 5.04 M

Mr. Charles Dadswell

(64)
Illumina Senior Vice President, General Counsel, Company Secretary
Compensation 3.56 M

Mr. Joydeep Goswami

(51)
Illumina Chief Financial Officer
Compensation 1.98 M

Ms. Aimee Hoyt

(51)
Illumina Chief People Officer
Compensation 864,073

Ms. Caroline Dorsa

(63)
Illumina Independent Director
Compensation 455,374
1
2
3
4

Illumina Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,950,840,700,640,570,60
Humanwell Healthcare A Stock
Humanwell Healthcare A
SupplierCustomer0,940,780,20-0,75-0,82
Merck & Co. Stock
Merck & Co.
SupplierCustomer0,930,840,36-0,10-0,54-0,42
Alexandria Real Estate Equities, Inc. Stock
Alexandria Real Estate Equities, Inc.
SupplierCustomer0,900,590,260,830,750,81
QIAGEN Stock
QIAGEN
SupplierCustomer0,880,13-0,220,430,330,64
ON24, Inc. Stock
ON24, Inc.
SupplierCustomer0,860,670,21-0,51
AIMS APAC REIT Stock
AIMS APAC REIT
SupplierCustomer0,800,570,330,820,840,51
Myriad Genetics Stock
Myriad Genetics
SupplierCustomer0,790,52-0,040,750,890,64
Roche Holding AG Stock
Roche Holding AG
SupplierCustomer0,790,840,280,90
CareDx Stock
CareDx
SupplierCustomer0,780,710,180,380,730,81
1
2

Most common questions regarding Illumina

What values and corporate philosophy does Illumina represent?

Illumina Inc represents values of advancing genomics and enabling researchers to unlock the power of the genome. With a strong corporate philosophy focused on innovation, collaboration, and customer-centricity, Illumina is committed to transforming human health by developing breakthrough technologies in genetic sequencing and analysis. By providing cutting-edge solutions, Illumina empowers scientists and healthcare professionals worldwide to make groundbreaking discoveries and personalized medicine advancements. As a leader in genomics, Illumina Inc strives to drive scientific and clinical progress, ultimately improving lives and shaping the future of genomic medicine.

In which countries and regions is Illumina primarily present?

Illumina Inc is primarily present in various countries and regions worldwide. With its global presence, Illumina serves customers and conducts business operations in North America, Europe, Asia Pacific, and Latin America. The company's headquarters are located in San Diego, California, United States. Illumina has established offices, manufacturing facilities, and collaborations across different nations, including but not limited to the United Kingdom, Germany, Australia, China, Japan, and Brazil. Through its expansive reach and network, Illumina continues to contribute to advancements in genomic research and personalized medicine on a global scale.

What significant milestones has the company Illumina achieved?

Illumina Inc has achieved numerous significant milestones. The company revolutionized genetic analysis by developing high-throughput DNA sequencing technologies. It introduced the first commercially available sequencing system, the Genome Analyzer, enabling unprecedented advancements in genomics research. Illumina's innovative technologies have played a pivotal role in driving breakthrough discoveries in fields like cancer research, rare disease diagnosis, and agriculture. The company's contributions have been recognized globally, and it has received various awards and recognitions for its exceptional products and services. Through continuous innovation and strategic collaborations, Illumina Inc remains at the forefront of genomics, continually expanding the boundaries of scientific knowledge.

What is the history and background of the company Illumina?

Illumina Inc. is a renowned genomics company with a rich history and background. Founded in 1998, Illumina has consistently been at the forefront of genomic research and has played a vital role in advancing the field of genetic sequencing. The company specializes in developing innovative technologies and solutions for genetic variation analysis, DNA sequencing, and genotyping. Illumina's cutting-edge platforms enable researchers to gain valuable insights into human health and disease, plant and animal genomics, and forensic genomics. With a global presence and a solid track record of delivering high-quality genomic tools, Illumina continues to make significant contributions to the scientific community and shape the future of genomic research.

Who are the main competitors of Illumina in the market?

The main competitors of Illumina Inc in the market include companies like Thermo Fisher Scientific, Pacific Biosciences, and Oxford Nanopore Technologies.

In which industries is Illumina primarily active?

Illumina Inc is primarily active in the biotechnology industry.

What is the business model of Illumina?

The business model of Illumina Inc focuses on developing and selling genetic sequencing and array-based solutions. Illumina specializes in the research, clinical, and applied markets and offers a wide range of products and services. Their innovative technologies enable researchers to sequence DNA, RNA, and whole genomes efficiently and accurately, facilitating various applications in genomics. By providing exceptional sequencing platforms, consumables, and data analysis tools, Illumina aims to empower scientists worldwide to unlock the power of the genome. With a strong commitment to advancing precision medicine, Illumina plays a significant role in catalyzing breakthrough discoveries and contributing to various scientific and medical advancements.

What is the P/E ratio of Illumina 2025?

The P/E ratio cannot be calculated for Illumina at the moment.

What is the P/S ratio of Illumina 2025?

The P/S cannot be calculated for Illumina currently.

What is the Quality Investing of Illumina?

The Quality Investing for Illumina is 2/10.

What is the revenue of Illumina 2025?

The expected Illumina revenue is 4.43 B USD.

How high is the profit of Illumina 2025?

The expected Illumina profit is 731.68 M USD.

What is the business model of Illumina

Illumina Inc. is a US company specializing in the field of genomics research. It was founded in 1998 by four biochemists and is headquartered in San Diego, California. Illumina is positioned as a leading provider of technologies for DNA and RNA sequencing. The company has five core business areas: genomics, oncology, reproductive and gynecology, agriculture, and forensics. Each of these areas has its own range of products and services. The genomics area is Illumina's largest business area and includes a wide range of solutions for DNA sequencing. These include both devices and software solutions for the analysis and interpretation of sequencing data. The oncology business area focuses on the development of diagnostic solutions for cancer. Illumina offers a range of services, including sequencing of tumor and normal tissues to identify genomic changes and make personalized treatment decisions. In the reproductive and gynecology area, Illumina provides solutions for prenatal diagnostics, including sequencing of the fetal genome. The company also has a comprehensive range of products for in vitro fertilization. In the agriculture business, Illumina offers solutions for genomics of livestock and crops. These solutions can be used for breeding livestock and crops to improve their productivity and health. In the forensics area, Illumina provides solutions for the identification and analysis of DNA traces. These solutions can be used for forensic investigations, identification of individuals, and monitoring of animal populations. Some of Illumina's most well-known products are the HiSeq and MiSeq sequencers, which are used for high-throughput sequencing. There are also cloud-based analysis solutions for interpreting the data, as well as solutions for quantitative PCR. Illumina has also focused on partnerships with other major companies. It collaborates with Roche, Qiagen, Pacific Biosciences, and Oxford Nanopore Technologies to expand and enhance its products and services. Overall, Illumina specializes in integrating genomics and bioinformatics solutions to improve the health and well-being of humans, animals, and plants. The company is a key player in the biotechnology industry and is expected to usher in a new era of personalized medicine.

What is the Illumina dividend?

Illumina pays a dividend of 0 USD distributed over payouts per year.

How often does Illumina pay dividends?

The dividend cannot currently be calculated for Illumina or the company does not pay out a dividend.

What is the Illumina ISIN?

The ISIN of Illumina is US4523271090.

What is the Illumina WKN?

The WKN of Illumina is 927079.

What is the Illumina ticker?

The ticker of Illumina is ILMN.

How much dividend does Illumina pay?

Over the past 12 months, Illumina paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Illumina is expected to pay a dividend of 0 USD.

What is the dividend yield of Illumina?

The current dividend yield of Illumina is .

When does Illumina pay dividends?

Illumina pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Illumina?

Illumina paid dividends every year for the past 0 years.

What is the dividend of Illumina?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Illumina located?

Illumina is assigned to the 'Health' sector.

Wann musste ich die Aktien von Illumina kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Illumina from 2/19/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/19/2025.

When did Illumina pay the last dividend?

The last dividend was paid out on 2/19/2025.

What was the dividend of Illumina in the year 2024?

In the year 2024, Illumina distributed 0 USD as dividends.

In which currency does Illumina pay out the dividend?

The dividends of Illumina are distributed in USD.

All fundamentals about Illumina

Our stock analysis for Illumina Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Illumina Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.